BIOMOX- amoxicillin tablet Virbac AH, Inc.

Approved by FDA under NADA # 065-492 BIOMOX® (amoxicillin tablets)

For use in DOGS only.

DESCRIPTION

BIOMOX® (amoxicillin tablets) are a broad-spectrum, semisynthetic antibiotic which provides bactericidal activity against a wide range of common gram-positive and gramnegative pathogens. Amoxicillin chemically is D-(-) α -amino-p-hydroxybenzyl penicillin trihydrate.

Inactive Ingredients

Dibasic Calcium Phosphate Dihydrate, Magnesium Stearate, Microcrystalline Cellulose and Sodium Starch Glycolate.

ACTION

Amoxicillin has bactericidal activity against susceptible organisms similar to that of ampicillin. It acts by inhibiting the biosynthesis of bacterial cell wall mucopeptides. Most strains of the following grampositive and gram-negative bacteria have demonstrated susceptibility to amoxicillin, both *in vitro and in vivo*: nonpenicillinase-producing staphylococci, alpha- and beta- hemolytic streptococci, Enterococcus faecalis, *Escherichia coli* and *Proteus mirabilis*. Amoxicillin does not resist destruction by penicillinase; therefore, it is not effective against penicillinase-producing bacteria, particularly resistant staphylococci. Most strains of *Enterobacter* and *Klebsiella* and all strains of *Pseudomonas* are resistant. Amoxicillin may be given without regard to meals because it is stable in gastric acid. It is rapidly absorbed following oral administration and diffuses readily into most body fluids and tissues. It diffuses poorly into the brain and spinal fluid except when the meninges are inflamed. Most of the amoxicillin is excreted in the urine unchanged.

INDICATIONS

BIOMOX® (amoxicillin tablets) are indicated for treatment of the following infections in dogs when caused by susceptible strains of organisms:

BACTERIAL DERMATITIS due to *Staphylococcus aureus, Strepto-coccus spp., Staphylococcus spp.,* and *Escherichia coli.*

SOFT TISSUE INFECTIONS

(abscesses, wounds, lacerations) due to *Staphylococcus aureus*, *Enterococcus faecalis*, *Escherichia coli*, *Proteus mirabilis*, and *Staphylococcus spp*.

With all antibiotic therapy, appropriate in vitro cultures and sensitivities should be conducted prior to treatment.

CONTRAINDICATIONS

Use of amoxicillin is contraindicated in animals with a history of an allergic reaction to penicillin.

ADVERSE REACTIONS

Amoxicillin is a semisynthetic penicillin and, therefore, has the potential for producing allergic reactions. Epinephrine and/or steroids should be administered if an allergic reaction occurs.

WARNINGS

For use in dogs only.

PRECAUTIONS

Until adequate reproductive studies are accomplished, Biomox® (amoxicillin tablets) should not be used in pregnant or breeding animals.

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DOSAGE AND ADMINISTRATION

The recommended dosage is 5 mg per pound of body weight administered twice daily for 5 to 7 days or 48 hours after all symptoms have subsided. If no improvement is noted in 5 days, the diagnosis should be reconsidered and therapy changed.

SUPPLY

Biomox® (amoxicillin tablets) are supplied in 50 mg, 100 mg and 200 mg concentrations in bottles of 500 tablets.


Manufactured for:

Virbac AH, Inc.

P.O. Box 162059 Fort Worth, TX 76161 1-800-338-3659

Printed in USA Rev. -06 05/19

© 2019 Virbac Corporation. All Rights Reserved.BIOMOX is a registered trademark of Virbac AH, Inc.



BIOMOX

amoxicillin tablet

Product Information

Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:51311-201

Route of Administration ORAL

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength

amoxicillin (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9) | AMOXICILLIN ANHYDROUS | 50 mg

Drodu		Lauia	<u>+:</u> ~~

roduct characteristics					
Color	white	Score	no score		
Shape	ROUND	Size	6mm		
Flavor		Imprint Code			
Contains					

P	Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:51311-201-50	500 in 1 BOTTLE				

Marketing I	Marketing Information						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date				
NADA	NADA065492	05/24/2010					

BIOMOX

amoxicillin tablet

Product Information						
Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC:51311-203			
Route of Administration	ORAL					

Active Ingredient/Active Moiety					
Ingredient Name	Basis of Strength	Strength			
amoxicillin (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	100 mg			

Product Characteristics					
Color	white	Score	no score		
Shape	ROUND	Size	10mm		
Flavor		Imprint Code			
Contains					

P	Packaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:51311-203-50	500 in 1 BOTTLE					

Marketing Information						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
NADA	NADA065492	05/24/2010				

віомох

amoxicillin tablet

Product Information

Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:51311-205

Route of Administration ORAL

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength

amoxicillin (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9) AMOXICILLIN ANHYDROUS 200 mg

Product Characteristics

Color	white	Score	no score
Shape	ROUND	Size	11mm
Flavor		Imprint Code	
Cambaina			

Contains

Packaging

# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:51311-205-50	500 in 1 BOTTLE		

Marketing Information

Marketing	Application Number or Monograph	Marketing Start	Marketing End
Category	Citation	Date	Date
NADA	NADA065492	05/24/2010	

Labeler - Virbac AH, Inc. (131568396)

Establishment

Name	Address	ID/FEI	Business Operations		
Medispray Laboratories Private Ltd		915793457	manufacture		

Establishment

Na me	Address	ID/FEI	Business Operations
Centrient Pharmaceuticals Netherlands		860184986	api manufacture

Name	Address	ID/FEI	Business Operations			
Alcami Missouri Corporation		117877975	analysis			

Establishment

Name	Address	ID/FEI	Business Operations
Alcami Carolinas Corporation		831351445	analysis

Revised: 1/2022 Virbac AH, Inc.